TACSTD2 and urothelial carcinoma: Considering the high frequency of TROP2 and/or EpCAM positive urothelial carcinomas and the low dynamic range of brightfield immunohistochemistry for protein quantification, immunofluorescence was used for the quantification of our IHC results in this study to search for a clinical relevance of subtle expression differences.